• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Significant overtreatment of blood pressure and diabetes present amongst older diabetics

byAnees DaudandJames Jiang
October 28, 2015
in Cardiology, Endocrinology, Public Health
Reading Time: 3 mins read
UTI associated with increased risk of preeclampsia
Share on FacebookShare on Twitter

1. Based on Veterans Affairs primary care data on older adults with longstanding diabetes, deintensification of hypertension therapy, not including angiotensin converting enzyme inhibitors (ACE-I) amongst patients with moderately low and very low blood pressures (BP) occurred less than 20% of the time.

2. Similarly, deintensification of diabetes therapy, not including metformin, amongst the same population with moderately low (HgbA1c 6-6.4%) and very low (HgbA1c <6%) blood sugars occurred less than 20% of the time.

Evidence Rating Level: 2 (Good)

Study Rundown: Treatment guidelines about tight control of diabetes and blood pressure in the appropriate clinical settings have significantly reduced the undertreatment of these conditions. However, overtreatment is the harm that can come from this. Based on the important study, Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, tight control of blood sugars and blood pressures in patients with longstanding diabetes leads to adverse outcomes, especially in older adults. Newer guidelines do reflect this, but the deintensification of therapy is not always done. This study, which evaluated data from Veterans Affairs primary care, was conducted to determine whether deintensification of blood pressure and tight diabetes control occurred in older adults with longstanding diabetes. The results of the study showed that in patients with moderately low (BP 120-129/65 mmHg) and very low (BP <120/65) blood pressures, fewer than 20% of them underwent deintensification of therapy. Similarly, the study showed that in patients with moderately low (HgbA1c 6-6.4%) and very low (HgbA1c <6%) blood sugars, fewer than 30% of them underwent deintensification of therapy.

The strength of the study was the size of the cohort evaluated, and maintaining definitions of categories of blood pressure and blood sugar similar to the ACCORD trial, from which the guidelines are based. The weaknesses were inability to capture changes in insulin regimen (only whether it was discontinued) in pharmacy records and the inability to capture changes in medications patients filled from outside pharmacies.

Click to read the study, published today in JAMA Internal Medicine

RELATED REPORTS

A health coaching intervention may improve blood pressure control in postpartum women

2 Minute Medicine Rewind August 10, 2026

Duodenal-jejunal bypass liners may improve glycemic control in patients with diabetes

Relevant Reading: Potential overtreatment of diabetes mellitus in older adults with tight glycemic control.

In-Depth [retrospective cohort]: This retrospective cohort study was based on data from the primary care setting of Veterans Affairs hospitals in the calendar year 2012. Two cohorts were made, one for blood pressure and the other for diabetes control, both consisting of patients with known diabetes and age greater than 70 years. Low dose ACE-I was not counted as an antihypertensive since it has other indications in this cohort, and metformin was not counted as continued diabetic treatment since it does not cause hypoglycemia. Patients with heart failure and cirrhosis were excluded. Blood pressures were defined as follows: very low (<120/65), moderately low (120-129/65), not low (>130/65), and high (>140/90). Diabetes, based on HgbA1c measurements, was defined as follows: very low (<6%), moderately low (6-6.4%), not low (≥6.5%), and high (>7.5%). The primary outcome was the percentage of patients in two aforementioned cohorts who underwent deintensification of therapy.

In the blood pressure cohort, 25 955 of 211 667 patients (12.4%) received treatment to achieve a moderate low blood pressure, and 81 226 patients (38.4%) developed a very low BP while on treatment. Chance of deintensification in patients with moderate low BP (16.0%) and very low BP (18.8%) was slightly higher compared to those with not low BP (15.1%). In the diabetes control cohort, 23 769 of 179 991 (13.2%) received treatment to achieve a moderately low HgbA1c, and 12 917 (7.2%) received treatment resulting in a very low HgbA1c. Chance of deintensification of therapy in the moderately low (20.9%) and very low (27.0%) categories was somewhat higher than in the not low (17.5%) category.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: blood pressurediabetes mellitushypertension
Previous Post

Early invasive strategy associated with reduced cardiac death after acute coronary syndrome

Next Post

Majority of Chinese counties exceed under-5 mortality reduction of Millennium Development Goal 4

RelatedReports

Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

A health coaching intervention may improve blood pressure control in postpartum women

August 12, 2026
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Weekly Rewinds

2 Minute Medicine Rewind August 10, 2026

August 10, 2026
Surgery

Duodenal-jejunal bypass liners may improve glycemic control in patients with diabetes

July 16, 2026
Chronic Disease

Telehealth yields modest improvements in diabetes outcomes 

June 22, 2026
Next Post
Successful regional implementation of pediatric chest pain algorithm

Majority of Chinese counties exceed under-5 mortality reduction of Millennium Development Goal 4

Food environment associated with gestational diabetes

Diabetes linked with 15% excess risk of death

Radiation plus hormone therapy may improve prostate cancer survival

Olaparib linked to increased response in metastatic, castration-resistant prostate cancer

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind October 12, 2026
  • Gepotidacin (Blujepa) is safe and effective in women with uncomplicated urinary tract infections
  • Most routine blood tests do not require prolonged fasting
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.